

REAL-LIFE USE OF CEFTAZIDIME-AVIBACTAM

T. BLANCO ESPESO¹, M. RODRIGUEZ JORGE¹, A. ROMERO RUÍZ¹, R. SÁNCHEZ DEL MORAL¹.
¹HOSPITAL JUAN RAMÓN JIMÉNEZ, HOSPITAL PHARMACY, HUELVA, SPAIN

4CPS-005

J01- ANTIBACTERIALS
FOR SYSTEMIC USE

BACKGROUND AND IMPORTANCE

Ceftazidime-avibactam is a novel synthetic beta-lactam/beta-lactamase inhibitor combination active against Ambler class A, including extended-spectrum β -lactamases (ESBLs) and KPC, some class D enzymes (OXA-48 carbapenemases) and AmpC enzymes producing bacterias. Pharmacy and therapeutics (PyT) committee protocol includes its use in targeted treatment in severe infections with KPC-or-OXA 48-producing bacteria and combined with aztreonam in metallo-beta-lactamase-producing bacteria (VIM). Empiric treatment in severe infections and risk of colonisation by carbapenemase-producing bacteria without bacterial culture results.

AIM AND OBJECTIVES

Analyse the degree of protocol compliance established by the PyT committee on the use of ceftazidime-avibactam.

METHODS AND MATERIALS


A retrospective observational study was carried out in all patients treated with ceftazidime-avibactam from January 2020 to June 2024. Collected data: demographics (age,sex), prescription service, indication, dosage, duration of treatment, isolated microorganism, adverse drug reactions.

Data sources: electronic prescription program and electronic medical records.

RESULTS

31 patients 
 64.5% 
 Median age: 63 years (IQR=77-55)

Prescribing services were icu and infectious diseases.
 In 5 patients the prescribed dose was adjusted according to renal function.
 The median duration of treatment was 7 days (IQR:3-11).



CONCLUSIONS AND RELEVANCE

The degree of compliance with the protocol established by the PyT committee was high. In our case, ceftazidime-avibactam was used for targeted treatment of complicated urinary tract infections and sepsis in most cases.

